1. Home
  2. GRND vs WVE Comparison

GRND vs WVE Comparison

Compare GRND & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grindr Inc.

GRND

Grindr Inc.

HOLD

Current Price

$11.99

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$7.08

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRND
WVE
Founded
2009
2012
Country
United States
Singapore
Employees
148
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.4B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
GRND
WVE
Price
$11.99
$7.08
Analyst Decision
Buy
Strong Buy
Analyst Count
6
16
Target Price
$19.67
$30.25
AVG Volume (30 Days)
1.3M
5.9M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
$23.08
N/A
Revenue Next Year
$17.04
$85.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
149.43
52 Week Low
$9.79
$5.02
52 Week High
$25.13
$21.73

Technical Indicators

Market Signals
Indicator
GRND
WVE
Relative Strength Index (RSI) 52.33 29.54
Support Level $11.83 $6.94
Resistance Level $12.90 $8.29
Average True Range (ATR) 0.45 0.71
MACD -0.06 -0.41
Stochastic Oscillator 34.23 26.99

Price Performance

Historical Comparison
GRND
WVE

About GRND Grindr Inc.

Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: